Amgen announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule. This first-in-human study was designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of AMG 133 in people with obesity and without diabetes (NCT04478708). These data will be presented as part of an oral presentation on, December 3, 2022 at the 20(th) World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference.
Market Closed -
Other stock markets
|
Pre-market 07:00:22 am | |||
262.7 USD | -0.53% | 265.6 | +1.11% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.80% | 141B | |
+27.97% | 672B | |
+23.64% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.13% | 211B | |
-0.47% | 203B | |
-10.06% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Presents New AMG 133 Phase 1 Clinical Data At Wcirdc 2022